Charlotte Rosen, Caroline Jacqmart, Corinne Charlier, Maurice Beghetti, Marie-Christine Seghaye
Centre Hospitalier Universitaire de Liège. Hôpitaux universitaires de Genève.
Belgium and Switzerland
Revue Medicale de Liege
Rev Med Liege 2024; 79: 104-109
DOI: Not Available
Abstract
Vasoreactive pulmonary arterial hypertension (PAH) in children is a form of idiopathic PAH that responds to vasoreactive testing with nitric oxide (NO) by a significant decrease of pulmonary vascular resistances and pressure. Oral calcium channel antagonists (CCA) that allow pulmonary arterial vasodilation are the treatment of choice. The therapeutic effect is strongly depending on adequate drug intake. In growing children, drug dose must be adapted to weight. In case of unavailability of low-dose pharmaceutical preparations, officinal formulations become mandatory. Officinal formulations may be related to a multitude of errors at different steps including prescription, transcription, preparation and administration. This may have life-threatening consequences for the child.To illustrate this, we report a case of a compounding error with underdosage of CCA, leading to acute cardiovascular failure in an adolescent with vasoreactive PAH.
Category
Class I. Pulmonary hypertension Associated with a Favorable Response to Nitric Oxide and Calcium Channel Blockers
Medical Therapy. Efficacy or Lack of Efficacy
Medical Therapy. Pharmacokinetics and Pharmacology
Age Focus: Pediatric Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: No (Article in French)